Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Abstracts
Book Review
Case Report
Case Series
CMAS‡ - Pancreas - EUS-FNA Cytopathology (PSC guidelines) S1:1 of 5
CMAS‡ - Pancreas - EUS-FNA Cytopathology (PSC guidelines) S1:3 of 5
CMAS‡ - Pancreas - EUS-FNA Cytopathology (PSC guidelines) S1:4 of 5
CMAS‡ - Pancreas -Sampling Techniques for Cytopathology (PSC guidelines) S1:2 of 5
CMAS‡ - Pancreas- EUS-FNA Cytopathology (PSC guidelines) S1:5 of 5
Commentary
Correction
CytoJournal Monograph Related Review Series
CytoJournal Monograph Related Review Series (CMAS), Editorial
CytoJournal Monograph Related Review Series: Editorial
Cytojournal Quiz Case
Editorial
Erratum
Letter to Editor
Letter to the Editor
Letters to Editor
Methodology
Methodology Article
Methodology Articles
Original Article
Pap Smear Collection and Preparation: Key Points
Quiz Case
Research
Research Article
Review
Review Article
Systematic Review and Meta Analysis
View Point
View/Download PDF

Translate this page into:

Research Article
2026
:23;
38
doi:
10.25259/Cytojournal_127_2025

Bioinformatics identification of forkhead box O3 and the proto-oncogene tyrosine-protein kinase receptor RET as aging-associated biomarkers linked to immune cell infiltration in Parkinson’s disease

Department of Neurology, Tongji University School of Medicine, Shanghai Tenth People’s Hospital, Shanghai, China
Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
Department of Nursing, School of Health, Wuhan University, Wuhan, China
School of Medicine, Shanghai University, Shanghai, China
Department of Neurology, Minhang Hospital, Fudan University, Shanghai, China
Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Author image
Corresponding authors: Yanxin Zhao, Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. zhao_yanxin@tongji.edu.cn
Author image
Lan Zheng, Department of Neurology, Minhang Hospital, Fudan University, Shanghai, China zhenglan1323@163.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Zheng H, Guan A, Li X, Zhang X, Zheng L, Zhao Y. Bioinformatics identification of forkhead box O3 and the protooncogene tyrosine-protein kinase receptor RET as aging-associated biomarkers linked to immune cell infiltration in Parkinson’s disease. CytoJournal. 2026;23:38. doi: 10.25259/Cytojournal_127_2025

Abstract

Objectives:

Parkinson’s disease (PD), the second most prevalent neurodegenerative disease, is closely linked to aging and immune system dysfunction. This study aims to explore potential aging-related biomarkers of PD and examine their diagnostic value, in addition to their relationship with immune cell infiltration, to identify novel therapeutic targets.

Methods:

Gene expression profiles from the gene expression omnibus (GEO) database (GSE20163, GSE20164, and GSE8397) were analyzed. Aging-related genes associated with PD were screened using weighted gene co-expression network analysis. Subsequent functional enrichment analysis, protein‒protein interaction (PPI) network mapping, and least absolute shrinkage and selection operator regression were used to identify key biomarker candidates. A receiver operating characteristic (ROC) curve analysis was applied to evaluate diagnostic efficacy. Immune cell infiltration was assessed through Spearman correlation analysis, and the expression of key biomarkers was validated in both cellular and animal PD models.

Results:

Eighteen aging-related genes were identified through a PPI network analysis. Seven genes, including forkhead box O3 (FOXO3) and the proto-oncogene tyrosine-protein kinase receptor rearranged during transfection (RET), showed potential as diagnostic biomarkers for PD. Gene set enrichment analysis revealed that these biomarkers correlated with immune cell infiltration patterns in PD patients. The ROC curve analysis indicated high diagnostic accuracy for these genes across multiple datasets (area under the curve = 96.3158). In vivo and in vitro validation confirmed significant changes in the expression of RET and FOXO3 in PD samples, highlighting their relevance as biomarkers.

Conclusion:

Our findings suggest that RET and FOXO3 are promising aging-related biomarkers for PD, potentially providing new insights into the early diagnosis and targeted treatment of PD. These biomarkers also reflect the complex interplay between aging, immunity, and PD pathogenesis.

Keywords

Aging
forkhead box O3
immune infiltration
parkinson’s disease
proto-oncogene tyrosine-protein kinase receptor RET

INTRODUCTION

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease and predominantly affects individuals aged ≥60 years.[1] With the aging of the global population, the incidence of PD is increasing substantially, with age being the most prominent risk factor for its development.[2] Typical clinical features of PD include motor impairments such as slowness of movement, stiffness, tremors, and balance issues. In contrast, non-motor symptoms, such as digestive problems and sleep disorders, can precede the motor symptoms by several years.[3] PD is pathologically characterized by the presence of Lewy bodies in dopaminergic neurons in the substantia nigra (SN).[4] Despite ongoing research efforts focused on identifying reliable biomarkers for early diagnosis, developing definitive diagnostic markers for PD remains a major challenge.[5,6]

Aging has been recognized as the most significant risk factor for PD, yet the exact relationship between aging and PD remains poorly defined.[7,8] With aging, increased oxidative stress,[9,10] neuroinflammation,[11] mitochondrial dysfunction, and cell death are considered common pathophysiological mechanisms.[8] Many aging-related genes are correlated with neurodegenerative diseases, although their specific involvement in PD pathogenesis remains poorly understood.[7] Accumulating evidence indicates that immune system aging, including inflammaging, immunosenescence, and age-acquired autoimmunity, is critically involved in the pathogenesis of PD, in which microglia and infiltrated immune cells mediate both neuroprotective and neurotoxic inflammatory processes.[7,12] Immune cell infiltration is thought to contribute to the occurrence and progression of PD during the prodromal phase, with various immune cells (e.g., monocytes, T lymphocytes, B lymphocytes, and neutrophils) potentially influencing dopaminergic neurons through complex interactions.[13,14] An exploratory study revealed that CD4+ and CD8+ T cells infiltrate the brain and recognize specific α-synuclein peptides, acting as antigen-presenting cells and promoting further CD8+ T-cell infiltration.[15,16] These cells drive neuroinflammation through interferon-γ and tumor necrosis factor-α secretion, directly exacerbating dopaminergic neuronal damage during early PD stages. Critically, aging potentiates this process by disrupting blood–brain barrier (BBB) integrity and inducing immunosenescence. The structural and functional disruption of the BBB induced by aging facilitates the entry of peripheral immune cells into the central nervous system (CNS) during the prodromal phase of PD. Immunosenescence alters the immune cell composition, characterized by a decrease in the number of naive T and B cells, the expansion of memory T cells, and an increase in the number of pro-inflammatory age-associated B cells, which collectively amplify the infiltration and neuroinflammatory responses of autoreactive CD4+/CD8+ T cells. Moreover, inflammation drives microglial activation and the sustained release of proinflammatory cytokines, creating a feedback loop that perpetuates BBB dysfunction and immune cell infiltration.[7,12,17] Thus, age-associated immune cell infiltration represents a bridge between immune aging and the onset of neurodegeneration, positioning it as a key target for early biomarker discovery.

Despite notable advances in identifying biomarkers linked to age-associated neurodegenerative disorders through comprehensive bioinformatics approaches,[18,19] reliable diagnostic biomarkers for PD derived from aging-related genes remain scarce, highlighting a critical translational gap in this field. A major unsolved challenge is the lack of minimally invasive peripheral biomarkers for the early diagnosis of PD. While several cerebrospinal fluid and neuroimaging biomarkers have been identified, they remain unavailable for large-scale screening. Current blood-based markers, such as total α-synuclein, lack specificity due to age-related and peripheral confounding factors, and few studies have integrated aging-specific gene signatures with immune cell infiltration dynamics to identify early diagnostic biomarkers for PD.[20] In this study, bioinformatics analysis and machine learning techniques were used to identify aging-related genes associated with PD. Furthermore, we combined the aging-related gene screen with the profile of infiltrating immune cells to identify peripheral biomarkers reflective of early CNS immune dysregulation in PD patients, which may also provide insights into the immune aging mechanisms underlying the early onset of PD.

MATERIAL AND METHODS

Data collection and processing

The gene expression datasets GSE20163, GSE20164, and GSE8397 were obtained from the publicly available National Center for Biotechnology Information (NCBI) gene expression omnibus (GEO) database (https://www. ncbi.nlm.nih.gov/geo/). These three datasets consist of data derived from SN tissues, including 25 healthy controls (HCs) and 38 patients with PD, and were utilized as the test dataset. In addition, GSE7621 (9 HCs and 16 PD patients) and GSE49036 (8 HCs and 15 PD patients) served as the validation datasets. Furthermore, 307 aging-related genes were extracted from the human aging gene database (HAGR)[21] (http://genomics.senescence.info/genes/).

Weighted gene co-expression network analysis (WGCNA)

WGCNA[22] was employed to identify the relationships between gene modules and PD. By employing the R package “WGCNA,” weighted co-expression networks were constructed using genetic and clinical data from GSE20163, GSE20164, and GSE8397. The slope was set to approximately 1, and the scale-free soft threshold power R2 was adjusted to approach 0.85 to convert the adjacency matrix into a topologically overlapping matrix. The adjacency matrix was then transformed into the topological overlap matrix (TOM) using an optimal power (β = 8). After the modules were identified, hierarchical clustering was applied to calculate the Eigen genes. Finally, Spearman’s correlation analysis was performed to evaluate the relationships among the different modules.

Functional enrichment analysis

Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were conducted using the clusterProfiler package in R to identify the functions of key genes involved in PD.[22] The analysis included biological processes, cellular components, and molecular functions, with statistical significance set at P < 0.05.

Protein–protein interaction (PPI) network

The online STRING platform (https://cn.string-db.org/) was utilized to construct the PPI network, and a combined interaction score threshold greater than 0.4 was applied. The network was visualized using Cytoscape.[23]

Validation of diagnostic risk models

The predictive performance of aging-associated genes for identifying PD in both the training and validation cohorts was assessed using least absolute shrinkage and selection operator (LASSO) regression and ROC curve analyses. The diagnostic accuracy was evaluated based on the area under the curve (AUC), which quantified the ability to distinguish PD patients from HCs.

Gene set enrichment analysis (GSEA)

The potential pathways related to the identified diagnostic genes were examined through GSEA implemented using the R package GSEA. Significant enrichment was defined as an adjusted P < 0.05.

Immune cell infiltration abundance analysis

Immune cell infiltration in PD and normal tissues was quantified using the ImmuCellAI platform new version (http://bioinfo.life.hust.edu.cn/web/ImmuCellAI/), covering 24 immune cell populations, including 18 T-cell subsets and six other immune cell types (DCs, B cells, macrophages, monocytes, neutrophils, and NK cells).[24] The correlations between the diagnostic genes and immune cell infiltration levels in PD patients were assessed through Spearman’s correlation analysis, and the results were visualized with an R-based heatmap.

Cell culture

Human neuroblastoma (SH-SY5Y) cells (SCSP-5014), purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences, were cultured in DMEM (41401ES76, YEASEN, China) or DMEM/F-12 (41406ES76, YEASEN, China) supplemented with 10% fetal bovine serum (FSP500, EXCELL), 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified incubator at 37°C with 5% CO2. Afterward, the cells were incubated with 500 µM 1-Methyl-4-phenylpyridinium (MPP+; M10041, AbMole, USA) to induce a PD cell model or with 200 µM H2O2 (Lircon, China) to induce oxidative damage in SH-SY5Y cells, as described in previous studies.[25,26] The cell lines were authenticated by short-tandem repeat profiling, and tests for mycoplasma contamination were confirmed to be negative.

Extraction of RNA followed by quantitative real-time polymerase chain reaction (qRT-PCR)

Total ribonucleic acid (RNA) was isolated from SH-SY5Y cells using TRIzol reagent (15596026CN, Invitrogen, USA) according to the manufacturer’s guidelines. The concentration and purity of the extracted RNA were determined using a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). One microgram of RNA was then reverse transcribed into complementary DNA (cDNA) using RNA-to-cDNA Master Mix (4387406; Applied Biosystems™, Thermo Scientific, USA) according to the provided instructions.

qRT-PCR was performed on a Rotor-Gene Q instrument (Qiagen, Germany) utilizing SYBR Premix Ex Taq II (RR041A, TaKaRa, Japan) to quantify RET and forkhead box O3 (FOXO3) gene expression. The thermal cycling conditions were as follows: initial denaturation at 95°C for 15 min, followed by 45 amplification cycles of 95°C for 5 s and 60°C for 30 s. Rotor-Gene Real-Time Analysis Software 6.0 was used for data analysis. Gene expression levels were normalized to those of the internal control GAPDH, and relative expression was calculated using the 2−ΔΔCt method. The following primers were used:

  • RET-forward 5’TCCTTTCCCTTACCCACCTTCAG3’,

  • RET-reverse 5’AGACCACAGCACCACAGACC3’,

  • FOXO3-forward 5’GCAGACCATCCAAGAGAACA AGC3’,

  • FOXO3-reverse 5’TGGCTAAGTGAGTCCGAAGTGAG3’,

  • GAPDH-forward 5’TCAAGGCTGAGAACGGGAAG3’,

  • GAPDH-reverse 5’CGCCCCACTTGATTTTGGAG3 ’.

In vivo experimental study

A PD animal model was established by intraperitoneally injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg; M0896, Sigma-Aldrich, USA) into C57BL/6 mice (age: 6-8 weeks, weight: 25 ± 2 g) for five consecutive days. Twenty-month-old aging mice on a C57BL/6J background were obtained from Phenotek Biotechnology Co., Ltd. (Shanghai, China). All mice were maintained in a specific pathogen-free facility under standardized conditions, including a constant temperature of 23 ± 2°C, a 12-h light/dark cycle, and a relative humidity of 60% ± 5%. Throughout the experiment, the animals had unrestricted access to standard chow and water. The mice were euthanized at the completion of the experiment using an intraperitoneal injection of pentobarbital sodium (110 mg/kg; P3761, Sigma, Merck, USA). All procedures involving animals were performed in compliance with the ARRIVE guidelines and Guidelines for the Care and Use of Laboratory Animals in China and received approval from the Experimental Animal Center of Tongji University School of Medicine (Approval No. 2023-MHFY-30JZS).

Immunohistochemistry

Following deep anesthesia, transcardial perfusion was performed using phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (PFA) in PBS. Afterward, the brains were fixed with 4% PFA for 24 h and sliced into 30 μm thick sections. The sections were incubated with an anti-RET antibody (ab134100, Abcam, UK), an anti-FOXO3 antibody (AFRM9032, AiFang Biological, China), or a tyrosine hydroxylase antibody (ab6211, Abcam, UK). The experiments followed the standard protocol, and the images were captured with an optical microscope (Axio Observer 7, Zeiss, Germany).

Mitochondrial ROS measurement

Mitochondrial ROS levels were detected using MitoSOX Red (S0061, Beyotime, China). The cells were incubated with a working solution containing MitoTracker (C1048, Beyotime, China; diluted 1:5000) and MitoSOX (1:1000 dilution in PBS) for 30 min at 37°C, washed with PBS, and then subjected to confocal microscopy (Olympus FV1200) for visualization.

Statistical analysis

Statistical analyses were conducted using R software (version 4.0.3) and GraphPad Prism (version 9.0). Spearman’s correlation analysis was performed to assess the relationships between variables. The data are presented as the means ± standard deviations (SDs), for comparisons between two groups, unpaired Student’s t-tests were employed, whereas one-way analysis of variance (ANOVA) was used to evaluate differences among multiple groups. When significant differences were detected by ANOVA, Tukey’s post hoc test was performed for pairwise comparisons. P <0.05 was considered to indicate statistical significance.

RESULTS

Research design flow chart

This flowchart outlines the process used to analyze gene expression [Figure 1]. The training dataset included 25 HCs and 38 PD patients from GSE20163, GSE20164, and GSE8397. The process began with aging-related differentially expressed genes (DEGs) identified through WGCNA. These genes were subjected to GO and KEGG enrichment analyses and PPI network construction. LASSO regression was subsequently applied, followed by a ROC curve analysis to determine the hub aging-related DEGs. These genes were subsequently validated using the GSE7621 (9 HCs and 16 PD patients) and GSE49036 (8 HCs and 15 PD patients) datasets. In parallel, an immune cell infiltration analysis was conducted using the ImmuCellAI tool, followed by Spearman’s correlation analysis. GSEA was performed to further explore the biological significance of the hub aging-related DEGs.

Bioinformatics workflow for identifying biomarkers related to aging and immune cell infiltration in PD patients. HC: Healthy control, PD: Parkinson’s disease, WGCNA: Weighted gene co-expression network analysis, DEGs: Differentially expressed genes, GO: Gene ontology, KEGG: Kyoto encyclopedia of genes and genomes, LASSO: Least absolute shrinkage and selection operator, PPI: Protein‒protein interaction, ROC: Receiver operating characteristic, GSEA: Gene set enrichment analysis.
Figure 1: Bioinformatics workflow for identifying biomarkers related to aging and immune cell infiltration in PD patients. HC: Healthy control, PD: Parkinson’s disease, WGCNA: Weighted gene co-expression network analysis, DEGs: Differentially expressed genes, GO: Gene ontology, KEGG: Kyoto encyclopedia of genes and genomes, LASSO: Least absolute shrinkage and selection operator, PPI: Protein‒protein interaction, ROC: Receiver operating characteristic, GSEA: Gene set enrichment analysis.

Identification of aging-related genes in PD patients

First, the WGCNA network was constructed using the GSE20163, GSE20164, and GSE8397 datasets. A scale-free network was then constructed with a β value of 8 (R2 = 0.85) [Figure 2a and b]. Twenty-six co-expression modules were subsequently identified [Figure 2c]. The correlation coefficients of each module with the PD group were calculated to further investigate the relationships between the modules and the phenotype. The results revealed that the turquoise module (r = 0.35, P = 1.4e−14) and the light cyan module (r = 0.77, P = 1.2e−40) exhibited significant positive correlations with the PD group [Figure 2d and e]. A total of 656 genes from the turquoise and light cyan modules were selected for further analysis.

Screen of Parkinson’s disease aging-related genes. (a) Network connectivity under different soft thresholds in Weighted gene co-expression network analysis (WGCNA). (b) Scaleless network display of the optimal soft threshold in WGCNA. (c) Correlation analysis results between the gene clustering module and PD. (d) Co-expression correlations among gene members in the turquoise gene module. (e) Co-expression correlation of gene members within the light cyan gene module.
Figure 2: Screen of Parkinson’s disease aging-related genes. (a) Network connectivity under different soft thresholds in Weighted gene co-expression network analysis (WGCNA). (b) Scaleless network display of the optimal soft threshold in WGCNA. (c) Correlation analysis results between the gene clustering module and PD. (d) Co-expression correlations among gene members in the turquoise gene module. (e) Co-expression correlation of gene members within the light cyan gene module.

Enrichment analysis of aging-related genes and PPI network analysis

We initially downloaded 307 aging-related genes from the aging database. We subsequently intersected the 656 module genes with the 307 aging-related genes to identify 18 aging-related genes significantly associated with the aging group [Figure 3a]. GO functional classification and KEGG enrichment analyses were performed to elucidate the molecular roles of these parkinson aging-related genes (PARGs). The cellular component analysis revealed that PARGs were predominantly localized in the cytosol, protein-containing complexes, and membrane protein complexes [Figure 3b]. The biological processes in which these genes were involved included the response to organic substances, cellular response to organic substances, intracellular signal transduction, and response to oxygen-containing compounds [Figure 3c]. The molecular function analysis indicated that the aging-related genes were linked to enzyme binding, signaling receptor binding, protein kinase binding, and kinase binding [Figure 3d]. Through the KEGG enrichment analysis, aging-associated genes were shown to participate in key pathways, including PI3K–Akt signaling, neurotrophin signaling, AMPK signaling, and pathways regulating longevity [Figure 3e]. A PPI network was constructed for the 18 aging-related genes, which included protein phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D), breast cancer susceptibility gene 1(BRCA1), small ubiquitin like modifier 1 (SUMO1), protein-L-isoaspartate (D-Aspartate) O-methyltransferase (PCMT1), eukaryotic translation elongation factor 1 epsilon 1 (EEF1E1), angiotensin II receptor type 1 (AGTR1), RET, FOXO3, succinate dehydrogenase complex subunit C (SDHC), CAMP responsive element binding protein 1 (CREB1), insulin receptor (INSR), insulin receptor substrate 1 (IRS1), suppressor of cytokine signaling 2 (SOCS2), growth hormone receptor (GHR), apoptosis inducing factor mitochondria associated 1 (AIFM1), mitogen-activated protein kinase Kinase Kinase 5 (MAP3K5), cell division cycle 42 (CDC42), and phospholipase C gamma 2 (PLCG2) [Figure 3f]. These findings suggest a significant imbalance in aging-related genes and pathways in PD patients.

Enrichment analysis and construction of a PPI network of aging-related genes. (a) Eighteen genes were obtained by crossing the differential genes and aging-related genes obtained from the WGCNA. (b-d) GO functional enrichment analysis (cellular components, biological processes, and molecular functions). (e) KEGG pathway enrichment analysis. (f) PPI network of PARGs. PPI: Protein‒protein interaction, WGCNA: Weighted gene co-expression network analysis, PARGs: Parkinson aging-related genes.
Figure 3: Enrichment analysis and construction of a PPI network of aging-related genes. (a) Eighteen genes were obtained by crossing the differential genes and aging-related genes obtained from the WGCNA. (b-d) GO functional enrichment analysis (cellular components, biological processes, and molecular functions). (e) KEGG pathway enrichment analysis. (f) PPI network of PARGs. PPI: Protein‒protein interaction, WGCNA: Weighted gene co-expression network analysis, PARGs: Parkinson aging-related genes.

Identification of optimal biomarkers in PD and analysis of the diagnostic risk model

The results are illustrated in LASSO coefficient trajectory plots [Figure 4a] and LASSO regression model diagrams [Figure 4b]. The results indicated that the LASSO regression model included seven genes: BRCA1, CREB1, FOXO3, INSR, RET, SDHC, and SUMO1. In addition, ROC curves were plotted [Figure 4c-e] for both the LASSO regression model and PD samples from the GSE7621 and GSE49036 datasets. The findings demonstrated that the PD diagnostic risk model exhibited high accuracy in both the test set (AUC = 96.3158) and the two validation sets, GSE7621 (AUC = 79.8611) and GSE49036 (AUC = 77.5000).

LASSO regression and analysis of the diagnostic model. (a) Variable trajectory diagram. (b) Diagram of the diagnostic risk model from the LASSO regression model. (c) The ROC curve of the diagnostic model. (d) The ROC curve of the samples in GSE7621. (e) The ROC curve of the samples from GSE49036. LASSO: Least absolute shrinkage and selection operator, ROC: Receiver operating characteristic.
Figure 4: LASSO regression and analysis of the diagnostic model. (a) Variable trajectory diagram. (b) Diagram of the diagnostic risk model from the LASSO regression model. (c) The ROC curve of the diagnostic model. (d) The ROC curve of the samples in GSE7621. (e) The ROC curve of the samples from GSE49036. LASSO: Least absolute shrinkage and selection operator, ROC: Receiver operating characteristic.

Verification of the expression levels of optimal biomarkers

Differences in the expression of optimal biomarkers between HCs and PD patients were further examined in two independent validation datasets (GSE7621 and GSE49036) to assess the roles of key aging-associated genes [Figure 5a-n]. The expression level of FOXO3 was increased [Figure 5c and j], whereas that of RET [Figure 5e and l] was significantly decreased in the PD group compared with the HC group across both datasets (GSE7621 and GSE49036). GSEA was employed to elucidate the relationships between gene expression and the biological processes, cellular components, and molecular functions affected in PD patients and to explore the overall impact of gene expression in PD samples [Figure 5o and p]. The findings indicated that the genes were significantly enriched in biological functions and signaling pathways associated with oxidative physiology, the tricarboxylic acid cycle (TCA) amino sugar, and nucleoside sugar metabolism and PD, but tended to be associated with cytokine and cytokine receptor interactions, the MAPK signaling pathway, linoleic acid metabolism, and the JAKSTAT signaling pathway [Figure 5o and p]. These results suggest that these genes play crucial roles in the development of PD. In addition, we observed that all the genes were associated with immune-related pathways.

Verification of the expression levels of aging-related genes and GSEA of aging-related genes. (a-g) In GSE7621, BRCA1 (a), CREB1 (b), FOXO3 (c), INSR (d), RET (e), SDHC (f), and SUMO1 (g) expression differed between HCs and PD patients. (h-n) In GSE49036, BRCA1 (h), CREB1 (i), FOXO3 (j), INSR (k), RET (l), SDHC (m), and SUMO1 (n) expression differed between HCs and PD patients. (o) GSEA showed that the module genes significantly affected oxidative physiology (P = 0, FDR = 0.0016), the TCA cycle (P = 0.002, FDR = 0.0087), amino sugar and nuclear sugar metabolism (P = 0.002, FDR = 0.014), and Parkinson’s disease (P = 0.0022, FDR = 0.0032). (p) GSEA showed that the module genes significantly affected cytokine and cytokine receptor interaction (P = 0.0078, FDR = 1), the MAPK signaling pathway (P = 0.0099, FDR = 0.67), linoleic acid metabolism (P = 0.012, FDR = 1), and the JAK-STAT signaling pathway (P = 0.012; FDR = 0.77). The screening criterion for the GSEA was an adjusted P < 0.05. FDR: False discovery rate, FOXO3: Forkhead box O3, HC: Healthy control, PD: Parkinson’s disease, GSEA: Gene set enrichment analysis.
Figure 5: Verification of the expression levels of aging-related genes and GSEA of aging-related genes. (a-g) In GSE7621, BRCA1 (a), CREB1 (b), FOXO3 (c), INSR (d), RET (e), SDHC (f), and SUMO1 (g) expression differed between HCs and PD patients. (h-n) In GSE49036, BRCA1 (h), CREB1 (i), FOXO3 (j), INSR (k), RET (l), SDHC (m), and SUMO1 (n) expression differed between HCs and PD patients. (o) GSEA showed that the module genes significantly affected oxidative physiology (P = 0, FDR = 0.0016), the TCA cycle (P = 0.002, FDR = 0.0087), amino sugar and nuclear sugar metabolism (P = 0.002, FDR = 0.014), and Parkinson’s disease (P = 0.0022, FDR = 0.0032). (p) GSEA showed that the module genes significantly affected cytokine and cytokine receptor interaction (P = 0.0078, FDR = 1), the MAPK signaling pathway (P = 0.0099, FDR = 0.67), linoleic acid metabolism (P = 0.012, FDR = 1), and the JAK-STAT signaling pathway (P = 0.012; FDR = 0.77). The screening criterion for the GSEA was an adjusted P < 0.05. FDR: False discovery rate, FOXO3: Forkhead box O3, HC: Healthy control, PD: Parkinson’s disease, GSEA: Gene set enrichment analysis.

Immune cell infiltration analysis

An immune cell infiltration analysis was performed using the expression matrix of PD and HC samples from the test datasets (GSE20163, GSE20164, and GSE8397). The abundance of 24 immune cells in both the PD and HC groups was calculated using the single-sample Gene Set Enrichment Analysis (ssGSEA) algorithm. A violin plot comparing the groups [Figure 6a-c] revealed significant differences in the levels of five types of immune cells, namely, monocytes, macrophages, natural killer T cells, naive CD4+ cells, and Tr1 cells (P ≤0.05). A correlation heatmap was subsequently generated to illustrate the correlation results of the immune cell infiltration abundances in the PD group [Figure 6d]. Within the samples from the PD group, the numbers of NKT cells were negatively correlated with monocyte (correlation coefficient = -0.38), naive CD4+ T-cell (correlation coefficient = -0.35), and Tr1 (correlation coefficient = -0.41) counts. In addition, naive CD4+ T cells were positively correlated with monocytes (correlation coefficient = 0.47) and Tr1 cells (correlation coefficient = 0.60).

Analysis of immune cell infiltration using the ImmuCellAI. (a) Comparative violin plot of the immune cell infiltration scores of PD patients and HCs. (b and c). Violin plots comparing the abundance of immune cell infiltration in HCs and PD patients. (d) The results of the correlation analysis of monocytes, macrophages, NKT cells, naive CD4+ cells, and Tr1 cells in the PD group. Significance levels were denoted as follows: ✶P < 0.05, ✶✶P < 0.002, ✶✶✶P < 0.0002; ✶✶✶✶P < 0.0001. HCs: Healthy controls, PD: Parkinson’s disease.
Figure 6: Analysis of immune cell infiltration using the ImmuCellAI. (a) Comparative violin plot of the immune cell infiltration scores of PD patients and HCs. (b and c). Violin plots comparing the abundance of immune cell infiltration in HCs and PD patients. (d) The results of the correlation analysis of monocytes, macrophages, NKT cells, naive CD4+ cells, and Tr1 cells in the PD group. Significance levels were denoted as follows: P < 0.05, P < 0.002, P < 0.0002; P < 0.0001. HCs: Healthy controls, PD: Parkinson’s disease.

Correlations between aging-related genes and immune cells

We observed significant differences in the expression levels of two aging-related genes, RET and FOXO3, between the PD and HC groups in both the GSE7621 and GSE49036 datasets. Therefore, we focused on these two genes for further analysis. An analysis of immune cell infiltration revealed significant differences in the abundance of the five immune cell types between the two groups, with all the differences reaching statistical significance. As shown in Figure 7, the results of Spearman’s correlation analysis indicated both positive and negative relationships. RET was negatively correlated with naive CD4+ T cells (R = -0.344, P = 0.006), macrophages (R = -0.290, P = 0.021), monocytes (R = -0.333, P = 0.008), and Tr1 cells (R = -0.458, P <0.001), whereas it was significantly positively correlated with NKT cells (R = 0.281, P = 0.026) [Figure 7a-e]. FOXO3 was not significantly correlated with naive CD4+ T cells, macrophages, monocytes, or NKT cells [Figure 7f-i] but was significantly positively correlated with Tr1 cells (R = 0.311, P = 0.013) [Figure 7j].

Correlations between aging-related genes and immune cells. (a-e) Diagrams showing the correlations of the RET expression level with the abundance of infiltrating naive CD4+ T cells (a), macrophages (b), monocytes (c), NKT cells (d), and Tr1 cells (e). (f-j). Diagrams showing the correlations of the Forkhead box O3 expression level with the abundance of infiltrating naive CD4+ T cells (f), macrophages (g), monocytes (h), NKT cells (i), and Tr1 cells (j).
Figure 7: Correlations between aging-related genes and immune cells. (a-e) Diagrams showing the correlations of the RET expression level with the abundance of infiltrating naive CD4+ T cells (a), macrophages (b), monocytes (c), NKT cells (d), and Tr1 cells (e). (f-j). Diagrams showing the correlations of the Forkhead box O3 expression level with the abundance of infiltrating naive CD4+ T cells (f), macrophages (g), monocytes (h), NKT cells (i), and Tr1 cells (j).

Verification of the expression of aging-related genes in in vivo and in vitro models

RNA expression was analyzed in cellular models of PD and aging, established through MPP+ or H2O2 treatment, to assess the feasibility of using aging-associated biomarker genes in PD diagnosis. MPP+ is taken up by neurons and accumulates in mitochondria, where it inhibits complex I of the electron transport chain. This inhibition leads to the production of reactive oxygen species (ROS), ultimately resulting in neuronal damage.[26] Costaining with MitoTracker and MitoSOX demonstrated robust mitochondrial ROS production induced by MPP+ in SHSY5Y cells, confirming the establishment of an in vitro PD model [Supplementary Figure 1a and b]. The qRT-PCR results showed that treatment with MPP+ or H2O2, which was used to induce PD or aging, led to the significant upregulation of FOXO3 expression and downregulation of RET expression in the cells [Figure 8a and b]. MPTP was used to establish an in vivo PD model, which caused a significant loss of tyrosine hydroxylase (TH)-positive neurons in the SN, a hallmark pathological feature of PD [Supplementary Figure 1c and d]. As shown in [Figure 8c and d], moderate FOXO3 immunoreactivity was detected in the SN of control mice. On MPTP treatment, which was used to induce the PD model, a marked increase in the FOXO3 staining intensity was observed in aged mice, indicating elevated levels of FOXO3 in both pathological and physiological aging states. In contrast, RET immunoreactivity was prominently expressed in the control group but dramatically decreased following MPTP treatment. Compared with control mice, aged mice also exhibited reduced RET expression, although the decrease was less pronounced in aged mice than in MPTP-treated mice [Figure 8e and f]. These findings suggest that these two aging-related genes may serve as reliable diagnostic biomarkers for PD.

Supplementary Figures
Forkhead box O3 (FOXO3) and RET expression in in vivo and in vitro models. (a and b) Quantitative real-time polymerase chain reaction analysis showing the relative mRNA expression levels of FOXO3 (a) and RET (b) in SH-SY5Y cells treated with MPP+ (500 µM) or H2O2 (200 µM) for 24 h compared with those in normal control (NC) cells. n = 3 independent experiments. (c) Representative images of immunohistochemical (IHC) staining for FOXO3 in the SN of mice from the control, MPTP-treated, and aging groups. Scale bar = 20 µm. (d) Quantification of the FOXO3 staining intensity in (c), normalized to that of the NC. n = 3 mice per group. (e) Representative images of IHC staining of RET in the SN across the same three groups. Scale bar = 20 µm. (f) Quantification of the RET staining intensity in (e), normalized to that of the NC. n = 3 mice per group. The data are presented as the means ± SDs. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. ✶P < 0.05, ✶✶✶P < 0.0002, ✶✶✶✶P < 0.0001, ns: Not significant. NC: Normal control, MPP+: 1-Methyl-4-phenylpyridinium, MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, H2O2: hydrogen peroxide, FOXO3: Forkhead box O3, RET: Proto-oncogene tyrosine-protein kinase receptor RET.
Figure 8: Forkhead box O3 (FOXO3) and RET expression in in vivo and in vitro models. (a and b) Quantitative real-time polymerase chain reaction analysis showing the relative mRNA expression levels of FOXO3 (a) and RET (b) in SH-SY5Y cells treated with MPP+ (500 µM) or H2O2 (200 µM) for 24 h compared with those in normal control (NC) cells. n = 3 independent experiments. (c) Representative images of immunohistochemical (IHC) staining for FOXO3 in the SN of mice from the control, MPTP-treated, and aging groups. Scale bar = 20 µm. (d) Quantification of the FOXO3 staining intensity in (c), normalized to that of the NC. n = 3 mice per group. (e) Representative images of IHC staining of RET in the SN across the same three groups. Scale bar = 20 µm. (f) Quantification of the RET staining intensity in (e), normalized to that of the NC. n = 3 mice per group. The data are presented as the means ± SDs. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. P < 0.05, P < 0.0002, P < 0.0001, ns: Not significant. NC: Normal control, MPP+: 1-Methyl-4-phenylpyridinium, MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, H2O2: hydrogen peroxide, FOXO3: Forkhead box O3, RET: Proto-oncogene tyrosine-protein kinase receptor RET.

DISCUSSION

PD is a progressive neurodegenerative disorder that is commonly associated with aging. In addition to motor symptoms such as tremors, postural imbalance, bradykinesia, and rigidity, PD is characterized by non-motor symptoms ranging from constipation to neuropsychiatric issues. A growing body of evidence has revealed that aging is one of the risk factors for neurodegeneration. It is crucial for the occurrence and development of PD. Moreover, some studies have demonstrated that dysregulation of the immune system aggravates neuronal damage caused by pathogenic factors.[1,27] Neuroinflammation is widely recognized as a key pathological characteristic of PD and involves the activation and interaction of various immune cells.[28] Consequently, a comprehensive understanding of immune cell infiltration patterns in PD patients and the identification of immune-related diagnostic biomarkers may have important implications for early diagnosis and targeted therapeutic interventions.

We utilized WGCNA to identify relevant genes from GEO datasets and to investigate the role of aging in PD. These genes were subsequently subjected to GO and KEGG analyses to determine their involvement in specific biological functions and signaling pathways. By constructing a PPI network, we further identified 18 aging-related genes, including PPM1D, BRCA1, SUMO1, PCMT1, EEF1E1, AGTR1, RET, FOXO3, SDHC, CREB1, INSR, IRS1, SOCS2, GHR, AIFM1, MAP3K5, CDC42, and PLCG2. GO enrichment and KEGG signaling pathway analyses revealed that aging-related genes were enriched mainly in intracellular transduction, receptor activity, inflammation-related pathways, immune-related pathways, and neurotrophin pathways. These results suggest that the identified genes may play key roles in the occurrence and progression of PD. The evidence suggests that the dysregulation of microglial activation is a potential cause of aging, resulting in an increase in interleukin-1 (IL-1), IL-6, and TNF-α levels in the cerebrospinal fluid, serum, and dopaminergic regions of the striatum among patients with PD.[12,27] The phosphoinositide 3-kinase-protein kinase B (PI3K-AKT), neurotrophin, and AMPK signaling pathways are involved in various physiological processes, including the regulation of the immune response and metabolism. The PI3K–Akt signaling pathway is responsible for regulating cell proliferation, apoptosis, and metabolism, which play important roles in PD.[29] In recent years, increasing evidence has shown that numerous natural compounds exert neuroprotective effects on PD by modulating the PI3K-AKT signaling pathway. These agents have been shown to preserve dopaminergic, hippocampal, and cortical neurons while also suppressing microglial activation, thereby contributing to the prevention and potential treatment of PD.[30] In addition, previous studies have reported that neurotrophin signaling, especially brain-derived neurotrophic factor – tropomyosin receptor kinase B (BDNF–TrkB) signaling, is involved in age-related cognitive diseases.[31] Next, we validated the expression levels of seven aging-related genes using the GSE7621 and GSE49036 datasets and found that RET and FOXO3 had diagnostic significance in the PD group. These results suggest that the two aforementioned genes are crucial contributors to the development of PD.

RET functions as the primary signaling receptor for glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) and is widely expressed in both the central and peripheral nervous systems, including in dopaminergic (DA) neurons.[32,33] RET activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) through the PI3K pathway, which is involved in a variety of different functions, including cell survival, differentiation, and proliferation.[33] Previous research has shown that RET signals with proteins encoded by PD-related genes, such as parkin, PINK1, and DJ-1, in both flies and mice, leading to alterations in mitochondrial function and ultimately contributing to the development of PD.[33] A recent study utilizing plasma proteomic analyses demonstrated that decreased RET protein levels were significantly associated with an increased incidence of PD. This association was observed as early as 15 years before the clinical diagnosis and exhibited a distinct fluctuation pattern characterized by “an early transient decline, brief recovery, and sustained reduction.”[34] GDNF supplementation and small-molecule RET agonists have been investigated as potential treatments for PD in preclinical models and clinical trials.[35] Although the predominant research focus has been on the role of RET in the survival of DA neurons, our study is the first to show a robust negative correlation between RET levels and the age-related infiltration of immune cells, including monocytes, macrophages, naive CD4+ T cells, and Tr1 cells, in PD patients. These findings broaden the understanding of the involvement of RET in PD pathogenesis. Given that immune cell infiltration occurs during the prodromal phase, RET represents a potential target for early intervention in PD.

FOXO3, a member of the forkhead box O (FOXO) transcription factor family, plays a pivotal role in regulating various signaling pathways by modulating the expression of genes involved in energy metabolism, the oxidative stress response, protein homeostasis, apoptosis, cell development and differentiation, metabolic regulation, autophagy, and lifespan maintenance.[36,37] Compared with those in healthy controls, elevated mRNA levels of FOXO3 were detected in the plasma of PD patients, indicating its potential utility as a peripheral biomarker for PD.[38] However, the precise role of FOXO3 in PD pathogenesis remains incompletely understood, as FOXO3 can mediate both neuroprotective and proapoptotic effects on DA neurons, depending on its various posttranslational modifications.[37] Our study is the first to identify an association between FOXO3 expression and Tr1 cell infiltration, providing a foundation for future research aimed at elucidating the regulatory mechanism by which FOXO3 contributes to PD pathogenesis.

Although our research focused predominantly on hub genes that are involved in immunological and metabolic processes, as well as those that may be involved in the PI3K-AKT and neurotrophin signaling pathways, the precise molecular mechanisms remain insufficiently elucidated. Modulations targeting FOXO3 and RET in PD models are warranted to provide causal evidence of their roles in PD pathogenesis. A further limitation is that co-expression experiments examining the potential interaction between FOXO3 and RET in age-related CNS immune cell infiltration were not performed. While previous studies have verified RET and FOXO3 as upstream and downstream targets of the PI3KAKT pathway, respectively, whether this pathway functionally connects RET and FOXO3 under specific pathological conditions remains unknown.[33,39] Collectively, the evidence from previous studies and this study suggests the following potential mechanistic axis: RET downregulation → PI3KAKT pathway inhibition → FOXO3 activation → immune cell infiltration → neurodegeneration. This axis may underlie age-related immune dysregulation in PD patients, which warrants further investigation in animal experiments. In addition, the animal model used in this study, the acute MPTP model, failed to fully recapitulate the complexity of human PD. While MPTP effectively induces motor impairments and SN dopaminergic neuronal loss acutely, it cannot replicate the α-synuclein pathology and the progressive aging process that are critical for PD pathogenesis.[26] Further work will focus on elucidating the regulatory pathways mediating FOXO3-RET interactions in age-related immune cell infiltration, particularly in more reliable PD models, to define their specific roles in neuroinflammation and neurodegenerative progression.

SUMMARY

This study highlights the critical roles of aging-related genes and immune cell infiltration in PD. RET and FOXO3 were identified as promising biomarkers that may improve diagnostic accuracy and offer new therapeutic targets for PD. These results underscore the importance of immune responses in PD pathogenesis and suggest that modulating immune pathways could be an effective strategy for managing this disease.

AVAILABILITY OF DATA AND MATERIALS

The data and materials that support the findings of this study are available from the corresponding author on reasonable request.

ABBREVIATIONS

AUC: Area under the curve

DEGs: Differentially expressed genes

FDR: False discovery rate

FOXO3: Forkhead box O3

GO: Gene ontology

GSEA: Gene set enrichment analysis

H2O2: Hydrogen peroxide

HAGR: Human aging gene database

HC: Healthy control

KEGG: Kyoto encyclopedia of genes and genomes

LASSO: Least absolute shrinkage and selection operator

MPP+: 1-Methyl-4-phenylpyridinium

MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

PARGs: Parkinson aging-related genes

PBS: Phosphate-buffered saline

PD: Parkinson’s disease

PFA: Paraformaldehyde

PPI: Protein-protein interaction

qRT-PCR: Quantitative reverse transcription polymerase chain reaction

RET: Proto-oncogene tyrosine-protein kinase receptor Ret

ROC: Receiver operating characteristic SN: Substantia nigra

TOM: Topological overlap matrix

WGCNA: Weighted gene co-expression network analysis

ACKNOWLEDGMENTS

Not applicable.

AUTHOR CONTRIBUTIONS

HZ: Methodology, investigation, bio-informatic analysis, data curation, writing, and original draft; AG and XL: Investigation, bioinformatic analysis, data curation, writing, review, and editing; XZ: Data curation, writing, review, and editing; LZ and YZ: Conceptualization, supervision, revising/reviewing, and funding acquisition. All authors gave final approval of the version to be published, and participated fully in the work, took public responsibility for appropriate portions of the content, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or completeness of any part of the work were appropriately investigated and resolved. All authors meet the authorship status of ICMJE.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was performed based on the ARRIVE guidelines and Guidelines for the Care and Use of Laboratory Animals in China, and it has been approved by the ethics committee of Tongji University School of Medicine, approval No. 2023-MHFY-30JZS. Consent to participate is not required as this study does not involve human subjects for clinical research.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

EDITORIAL/PEER REVIEW

To ensure the integrity and highest quality of CytoJournal publications, the review process of this manuscript was conducted under a double-blind model (authors are blinded for reviewers and vice versa) through an automatic online system.

FUNDING: This research was funded by the STI2030-Major Projects (2021ZD0201806 to YXZ), Shanghai Hospital Development Center Foundation (SHDC22024234 to YXZ), and Minhang Hospital of Fudan University (2025MHBJ03 to LZ).

References

  1. , , . Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101-13.
    [CrossRef] [PubMed] [Google Scholar]
  2. . Global, regional, and national burden of Parkinson's disease 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939-53.
    [Google Scholar]
  3. , , , , , , et al. Pathophysiology of motor dysfunction in Parkinson's disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis. 2016;2016:9832839.
    [CrossRef] [PubMed] [Google Scholar]
  4. . Protein stability and aggregation in Parkinson's disease. Biochem J. 2008;413:1-13.
    [CrossRef] [PubMed] [Google Scholar]
  5. , . Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. 2015;21:87-94.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , , et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11:301-9.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , , , , et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565-81.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , . Aging and Parkinson's disease: Different sides of the same coin? Mov Disord. 2017;32:983-90.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021;599:650-6.
    [CrossRef] [PubMed] [Google Scholar]
  10. , , , , . Ageing, age-related diseases and oxidative stress: What to do next? Ageing Res Rev. 2020;57:100982.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , , , , . mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging. 2006;27:717-22.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , , , . Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657-73.
    [CrossRef] [PubMed] [Google Scholar]
  13. . The identification of alpha-synuclein as the first Parkinson disease gene. J Parkinsons Dis. 2017;7(s1):S43-9.
    [CrossRef] [PubMed] [Google Scholar]
  14. , , , , . T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an a-synuclein rat model of Parkinson's disease. J Neuroinflammation. 2020;17:242.
    [CrossRef] [PubMed] [Google Scholar]
  15. , , , , , , et al. The immune system in Parkinson's disease: What we know so far. Brain. 2024;147:3306-24.
    [CrossRef] [PubMed] [Google Scholar]
  16. , , , , , , et al. Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Sci Transl Med. 2024;16:eadm8563.
    [CrossRef] [PubMed] [Google Scholar]
  17. , , , , . Aging and neurodegenerative disease: Is the adaptive immune system a friend or foe? Front Aging Neurosci. 2020;12:572090.
    [CrossRef] [PubMed] [Google Scholar]
  18. , , , , , , et al. Revealing a novel contributing landscape of ferroptosis-related genes in Parkinson's disease. Comput Struct Biotechnol J. 2022;20:5218-25.
    [CrossRef] [PubMed] [Google Scholar]
  19. , , , , , , et al. Identification and validation of key molecules associated with humoral immune modulation in Parkinson's disease based on bioinformatics. Front Immunol. 2022;13:948615.
    [CrossRef] [PubMed] [Google Scholar]
  20. , , , , , , et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 2019;18:573-86.
    [CrossRef] [PubMed] [Google Scholar]
  21. , , , , , , et al. Human ageing genomic resources: New and updated databases. Nucleic Acids Res. 2018;46:D1083-90.
    [CrossRef] [PubMed] [Google Scholar]
  22. , . WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
    [CrossRef] [PubMed] [Google Scholar]
  23. , , , . Cytoscape stringapp: Network analysis and visualization of proteomics data. J Proteome Res. 2019;18:623-32.
    [CrossRef] [PubMed] [Google Scholar]
  24. , , , , , , et al. ImmuCellAI: A unique method for comprehensive T-Cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci (Weinh). 2020;7:1902880.
    [CrossRef] [PubMed] [Google Scholar]
  25. , , , , . Lithium inhibits oxidative stress-induced neuronal senescence through miR-34a. Mol Biol Rep. 2021;48:4171-80.
    [CrossRef] [PubMed] [Google Scholar]
  26. . Experimental models of Parkinson's disease. Nat Rev Neurosci. 2001;2:325-34.
    [CrossRef] [PubMed] [Google Scholar]
  27. , . Cellular senescence in neurodegenerative diseases. Front Cell Neurosci. 2020;14:16.
    [CrossRef] [PubMed] [Google Scholar]
  28. , , , , , . Neurodegeneration and inflammation-an interesting interplay in Parkinson's disease. Int J Mol Sci. 2020;21:8421.
    [CrossRef] [PubMed] [Google Scholar]
  29. , , , , , . PI3K/AKT signal pathway: A target of natural products in the prevention and treatment of Alzheimer's disease and Parkinson's disease. Front Pharmacol. 2021;12:648636.
    [CrossRef] [PubMed] [Google Scholar]
  30. , , , , , , et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol. 2017;155:96-119.
    [CrossRef] [PubMed] [Google Scholar]
  31. , . The role of neurotrophin signaling in age-related cognitive decline and cognitive diseases. Int J Mol Sci. 2022;23:7726.
    [CrossRef] [PubMed] [Google Scholar]
  32. , . Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease. Cell Tissue Res. 2020;382:147-60.
    [CrossRef] [PubMed] [Google Scholar]
  33. , . GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021;153:105298.
    [CrossRef] [PubMed] [Google Scholar]
  34. , , , , , , et al. Large-scale proteomic analyses of incident Parkinson's disease reveal new pathophysiological insights and potential biomarkers. Nat Aging. 2025;5:642-57.
    [CrossRef] [PubMed] [Google Scholar]
  35. , . Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic. Neural Regen Res. 2022;17:1462-7.
    [CrossRef] [PubMed] [Google Scholar]
  36. , , , , , , et al. Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Mol Neurodegener. 2009;4:32.
    [CrossRef] [PubMed] [Google Scholar]
  37. , , , , , , et al. FOXO3 determines the accumulation of a-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet. 2014;23:1435-52.
    [CrossRef] [PubMed] [Google Scholar]
  38. , , , , , , et al. Revealing novel genes related to Parkinson's disease pathogenesis and establishing an associated model. Neuroscience. 2024;544:64-74.
    [CrossRef] [PubMed] [Google Scholar]
  39. , , . Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021;20:21-38.
    [CrossRef] [PubMed] [Google Scholar]
Show Sections